A new study conducted by Washington University School of Medicine in the USA found that those who use immune-suppressing drugs for inflammatory diseases such as rheumatoid arthritis (inflammatory rheumatism) multiple sclerosis and ulcerative colitis may have a lower response to Pfizer / BioNTech and Moderna’s Covid-19 vaccines. was put.
DROP IN ANTIBODY LEVELS CHANGED BETWEEN 3 TO 36 FLOORS
In the study, published as a preprint in medRxiv, the researchers compared the antibody levels and virus neutralization of 133 people with autoimmune diseases who had been fully vaccinated with those of a healthy control group. In the results, it was seen that the antibody response of those using drugs that suppress the immune system was 3 to 36 times lower.
“RELIABLE MOST PATIENTS AFTER VACCINE FORMATION OF ANTIBODIES”
“Most patients participating in the study were able to generate antibody responses in response to Covid-19 vaccination, which is reassuring,” said Alfred Kim, one of the study’s authors. However, it is not yet clear whether decreasing antibody levels will result in protection from infection or hospitalization, ”he said.
However, Kim noted that there was a 10-fold decrease in vaccine-induced antibody levels seen in patients routinely using steroids such as prednisone and methylprednisolone, and a 36-fold decrease in those using Roche’s drug Rituxan (rituximab) and drugs that deplete B cells, including Ocrevus (ocrelizumab). told.
On the other hand, with inflammatory rheumatism drugs commonly used in the class known as TNF inhibitors such as Abbvie’s Humira (adalimumab) and Amgen’s Enbrel (etanercept); It has been noted that those using JAK inhibitors such as Pfizer’s Xeljanz (tofacitinib), intestinal-specific agents such as Takeda Pharmaceutical Co’s Entyvio (vedolizumab), and IL-12/23 inhibitors including Johnson & Johnson’s Stelara (ustekinumab) have been noted to have lesser levels of antibody levels.
DRUG AGAINST CORONA VIRUS HOPE: MOLNUPIRAVIR